GlassScriptPhysician profile
Albert P Lee
NPI 1053335505
$744.51
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $79.39 · 2021: $123 · 2022: $95.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $297.46 | 2020-2022 | |
| Amgen INC. | $175.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.56 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.45 | 2019 | |
| Abbott Laboratories | $23.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.50 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.